Acute Myeloid Leukemia (AML) is a type of cancer that originates in the bone marrow, which is responsible for producing vital blood cells, including red blood cells (RBCs), white blood cells (WBCs), and platelets. These cells play critical roles in oxygen transport, fighting infections, and blood clotting. However, in AML, this process becomes disrupted, particularly affecting a type of white blood cell known as the myeloblast.
AML causes these immature myeloblasts to multiply uncontrollably, preventing the production of healthy, mature blood cells. As a result, symptoms such as fatigue, frequent infections, easy bruising, and bleeding start to manifest as the number of normal blood cells decreases.
According to recent data from the Indian Council of Medical Research (ICMR), leukemia, including AML, is the second most common blood cancer in India, and the number of cases has been steadily rising. Early diagnosis and treatment are critical in managing the condition effectively.
Types of Acute Myeloid Leukemia (AML):
- Newly Diagnosed AML: This refers to patients who are diagnosed with AML for the first time and do not have a history of other blood disorders.
- Secondary AML: This occurs in patients who previously had a hematological disorder, such as myelodysplastic syndrome (MDS), or developed AML as a result of exposure to cytotoxic therapies.
- Relapsed AML: Patients who achieved remission after initial treatment but later experienced a return of the disease are diagnosed with relapsed AML.
- Refractory AML: This term describes AML that does not respond to initial treatment.
Tibsovo (Ivosidenib 250 MG) Treatment for AML:
AML is often driven by genetic mutations, including mutations in the IDH1 gene. Genetic testing can help healthcare professionals determine the most appropriate treatment. One innovative treatment for IDH1-mutated AML is Tibsovo (Ivosidenib), developed by Servier Pharmaceuticals.
Tibsovo is a targeted therapy, available in 250 mg tablets, specifically designed to combat AML with an IDH1 mutation. Research shows that about 10% of patients with AML have this mutation. Instead of traditional chemotherapy, which kills both healthy and cancerous cells, Tibsovo targets only the mutated cells, helping myeloblasts mature into normal, functional WBCs.
Tibsovo’s Efficacy: According to clinical studies, Tibsovo has shown promise in treating relapsed or refractory AML patients with the IDH1 mutation. Recent data indicates that over 30% of patients treated with Tibsovo achieved complete remission or remission with partial blood recovery. This breakthrough offers new hope to patients with few treatment options.
How Tibsovo Works?
Tibsovo acts by inhibiting the IDH1 mutation, allowing abnormal myeloblasts to mature into normal WBCs. This treatment helps restore normal blood counts without affecting healthy cells. Moreover, Tibsovo is often combined with azacitidine, another medication, to enhance its effectiveness.
How and Where to Buy Tibsovo in India?
While Tibsovo is not registered in India, it can be legally imported. Patients or healthcare providers must submit the necessary documentation to obtain an import permit. For those looking to buy Tibsovo 250 mg tablets, contacting a trusted importer like Indian Pharma Network (IPN) is essential. IPN, a WHO GDP and ISO 9001:2015 certified pharmaceutical wholesaler/supplier/importer, specializes in the supply of rare medicines, including Tibsovo.
To inquire about Tibsovo’s price and availability, you can contact IPN via Call/WhatsApp: +919310090915 or TOLL-FREE: 1800-889-1064.
Frequently Asked Questions (FAQs):
What are the early symptoms of Acute Myeloid Leukemia?
Early symptoms of AML may include persistent fatigue, frequent infections, easy bruising or bleeding, shortness of breath, and pale skin. As AML progresses, these symptoms can worsen.
How is Acute Myeloid Leukemia Diagnosed?
AML is diagnosed through blood tests, bone marrow biopsies, and genetic testing to identify mutations, such as the IDH1 mutation, that may influence treatment options.
What is the role of Tibsovo in treating AML?
Tibsovo is a targeted therapy specifically designed for patients with an IDH1 mutation. It works by blocking the mutated IDH1 gene, allowing abnormal myeloblasts to mature into healthy WBCs.
Is Tibsovo more effective than traditional chemotherapy?
Tibsovo works differently than chemotherapy. It targets only cancerous cells with the IDH1 mutation, whereas chemotherapy affects all rapidly dividing cells, including healthy ones. Tibsovo is often used in patients who cannot tolerate traditional chemotherapy or who have relapsed or refractory AML.
How can I access Tibsovo in India?
Although Tibsovo is not registered in India, it can be legally imported through a trusted supplier like the Indian Pharma Network (IPN). Kindly Call/WhatsApp: +91931009091 to buy Tibsovo online in India. IPN facilitates the legal supply of Tibsovo, ensuring patients receive genuine medicine.
Conclusion:
Acute Myeloid Leukemia is a challenging diagnosis, but treatments like Tibsovo offer new hope for those with specific genetic mutations like IDH1. The advancements in targeted therapies bring us closer to more effective and less invasive treatments for AML patients. If you or a loved one is considering Tibsovo for treatment, understanding the process of legal importation through the Indian Pharma Network (IPN) can make access to this life-changing medication smoother and more reliable.
For further inquiries and assistance, please reach out to us via Call/WhatsApp: +919310090915 or TOLL-FREE: 1800-889-1064.
